Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Clene Inc.NASDAQ: CLNN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -2266.7%

Gross margin was -2266.7% in Q1 FY2026, down 2342.0 pp from a year earlier. On a trailing-twelve-month basis it was -182.1%, down 260.9 pp year over year. Over 3 fiscal years it narrowed by 16.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-2266.7%-2336.8 pp QoQ
Last fiscal yearDec 2025
78.5%-1.0 pp YoY
LTMMar 2026
-182.1%-260.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2342.0 pp——
1 year-1.0 pp——
3 years-16.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
78.5%
Year-over-year change
-1.0pp

Gross Margin vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's LTM Mar 2026 gross margin of -182.1% is the lowest of the 8 companies compared; the peer median is 89.4%.
  • Its year-over-year change of -260.9 pp is the lowest of 7, against a peer median of +4.0 pp.
  • Over three fiscal years its change of -16.0 pp compares with a peer median of -4.1 pp.
CLNN Competitors Peer median
Gross Margin for CLNN and competitors
Company Period LTM level YoY 3-year change
CNTBConnect Biopharma Holdings LimitedFY2025100.0% +0.0 pp—
COYACoya Therapeutics, Inc.LTM Mar 202699.8% +378.1 pp—
OVIDOvid Therapeutics Inc.LTM Mar 202699.5% -0.5 pp-4.1 pp
WHWKWhitehawk Therapeutics IncFY202589.4% +197.4 pp+212.8 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
ORMPOramed Pharmaceuticals Inc.FY20250.7% —-99.4 pp
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
CLNNClene Inc.LTM Mar 2026-182.1% -260.9 pp-16.0 pp
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding CLNN) 89.4%+4.0 pp-4.1 pp

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue723K473K654K342K200K
Cost of Revenue289K26K121K70K43K
Gross Profit434K447K533K272K157K
Gross Margin60.0%94.5%81.5%79.5%78.5%
Research & Development28.42M31.92M26.66M20.06M14.01M
Selling, General & Admin18.81M16.16M14.42M13.31M9.23M
Operating Expenses50.41M48.86M41.07M33.37M23.24M
Depreciation & Amortization955K1.02M1.71M1.65M1.5M
EBITDA(8.34M)(25.6M)(43.24M)(33.69M)(22M)
EBITDA Margin-1153.9%-5412.9%-6611.8%-9851.2%-10998.0%
Operating Income(49.98M)(48.41M)(40.54M)(33.09M)(23.08M)
Operating Margin-6912.6%-10234.5%-6198.8%-9676.3%-11541.5%
Interest Income001.39M865K223K
Interest Expense870K3.3M4.56M4.06M2.68M
Other Income / Expenses39.81M18.49M(8.96M)(6.31M)(3.09M)
Income Before Tax(10.17M)(29.92M)(49.5M)(39.4M)(26.17M)
Pre-Tax Margin-1406.4%-6325.2%-7569.4%-11520.5%-13086.5%
Income Tax Expense(428K)0000
Net Income(9.74M)(29.92M)(49.5M)(39.4M)(26.17M)
Net Margin-1347.2%-6325.2%-7569.4%-11520.5%-13086.5%
EPS (Basic)(3.16)(4.69)(9.43)(5.67)(2.65)
EPS (Diluted)(3.16)(4.69)(9.43)(5.67)(2.65)
Weighted Avg Shares3.08M3.26M5.25M6.95M9.86M
Weighted Avg Shares (Diluted)3.08M3.26M5.25M6.95M9.86M

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.